Skip to main content
SpringerLink
Log in

14-Amino-4,5-Epoxymorphinan Derivatives and Their Pharmacological Actions

  • Chapter
  • First Online:
Chemistry of Opioids

Part of the book series: Topics in Current Chemistry ((TOPCURRCHEM,volume 299))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

CBM:

Cyclobutylmethyl

CPM:

Cyclopropylmethyl

DOR:

Delta opioid receptor

GTPγS:

Guanosine 5′-O-[gamma-thio]triphosphate

i.c.v.:

Intracerebroventricular

i.p.:

Intraperitoneal

KOR:

Kappa opioid receptor

MOR:

Mu opioid receptor

s.c.:

Subcutaneous

TF:

Tail flick

TW:

Tail withdrawal

References

  1. Viscusi ER, Gan TJ, Leslie JB, Foss JF, Talon MD, Du W, Owens G (2009) Peripherally acting μ-opioid receptor antagonists and postoperative ileus: mechanisms of action and clinical applicability. Anesth Analg 108:1811–1822

    Article  CAS  Google Scholar 

  2. Buckett WR (1964) The relationship between analgesic activity, acute toxicity and chemical structure in esters of 14-hydroxycodeinone. J Pharm Pharmacol 16:68T–71T

    Google Scholar 

  3. Buckett WR (1965) Some pharmacological studies with 14-(cinnamoyloxy)codeinone. J Pharm Pharmacol 17:759–760

    CAS  Google Scholar 

  4. Buckett WR, Bosman HH (1972) New morphinone derivatives and their preparation. UK Patent 1 300 419

    Google Scholar 

  5. Bentley KW, Horsewood P, Kirby GW, Singh S (1969) Diels-Alder adducts from thebaine and nitroso-arenes. J Chem Soc D:1411

    Google Scholar 

  6. Schwab L (1980) 14-(Arylhydroxyamino)codeinones and derivatives as analgetics and antagonists. J Med Chem 23:698–702

    Article  CAS  Google Scholar 

  7. Allen RM, Kirby GW, McDougall DJ (1981) The nitration of thebaine with tetranitromethane. J Chem Soc Perkin Trans I 26:1143–1147

    Article  Google Scholar 

  8. Kobylecki RJ, Guest IG, Lewis JW, Kirby GW (1980) 14-Amino derivatives of morphine, methods of making them and analgesic compositions containing them. US Patent 4241066

    Google Scholar 

  9. Kobylecki RJ, Guest IG, Lewis JW, Kirby GW (1980) 14-Amino derivatives of morphine, methods of making them and analgesic compositions containing them. US Patent 4241067

    Google Scholar 

  10. Horsewood P, Kirby GW (1980) Preparation of 14-beta-hydroxyamino and 14-beta-aminocodeinone from thebaine. J Chem Res (S) 401:(M)4880

    Google Scholar 

  11. Archer S, Seyed-Mozaffari A, Osei-Gyimah P, Bidlack JM, Abood LG (1983) 14β-(2-Bromoacetamido)morphine and 14β-(2-bromoacetamido)morphinone. J Med Chem 26:1775–1777

    Article  CAS  Google Scholar 

  12. Kirby GW, Sweeney JG (1973) Nitrosocarbonyl compounds as intermediates in the oxidative cleavage of hydroxamic acids. J Chem Soc Chem Commun:704–705

    Google Scholar 

  13. Kirby GW, McLean D (1985) An efficient synthesis of 14β-aminocodeinone from thebaine. J Chem Soc Perkin Trans I 1443–1445

    Google Scholar 

  14. Lewis J, Smith C, McCarthy P, Walter D, Kobylecki R, Myers M, Haynes A, Lewis C, Waltham K (1988) New 14-aminomorphinones and codeinones. NIDA Res Monogr 90:136–143

    CAS  Google Scholar 

  15. Sebastian A, Bidlack JM, Jiang Q, Deecher D, Teitler M, Glick SD, Archer S (1993) 14β-[(p-Nitrocinnamoyl)amino]morphinones, 14β-[(p-nitrocinnamoyl)amino]-7,8-dihydromorphinones, and their codeinone analogues: synthesis and receptor activity. J Med Chem 36:3154–3160

    Article  CAS  Google Scholar 

  16. Bidlack JM, Kaplan RA, Sebastian A, Seyed-Mozaffari A, Hutchinson I, Archer S (1995) N-Mmethyl and N-cyclopropylmethyl-14α, 14′β-[dithiobis[(2-oxo-2, 1-ethanediyl)imino]]bis(7,8-dihydro-5β-methyl-morphinone) MET-TAMO and N-CPM-MET-TAMO: synthesis and opioid binding properties. Bioorg Med Chem Lett 5:1695–1700

    Article  CAS  Google Scholar 

  17. Nieland N (1998) Investigations of derivatives of 14β-amino-7,8-dihydromorphinone. PhD Thesis, University of Bristol

    Google Scholar 

  18. Rennison D, Moynihan H, Traynor JR, Lewis JW, Husbands SM (2006) Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effects of changes to the C14-amino to aryl ring linker chain. J Med Chem 49:6104–6110

    Article  CAS  Google Scholar 

  19. Nieland NPR, Moynihan H, Carrington S, Broadbear J, Woods JH, Traynor JR, Husbands SM, Lewis JW (2006) Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effect of substitution in the aromatic ring of cinnamoylaminomorphinones and codeinones. J Med Chem 49:5333–5338

    Article  CAS  Google Scholar 

  20. Grundt P, Jales AJ, Traynor JR, Lewis JW, Husbands SM (2003) 14-Amino, 14-alkylamino- and 14-acylamino analogs of oxymorphindole. Differential effects on opioid receptor binding and functional profiles. J Med Chem 43:1563–1566

    Article  Google Scholar 

  21. Husbands SM, Sadd J, Broadbear JH, Woods JH, Martin J, Traynor JR, Aceto MD, Bowman ER, Harris LS, Lewis JW (1998) 3-Alkyl ethers of clocinnamox: delayed long-term μ-antagonists with variable μ efficacy. J Med Chem 41:3493–3498

    Article  CAS  Google Scholar 

  22. Aceto MD, Bowman ER, Harris LS, May EL (1989) Dependence studies of new compounds in the rhesus monkey, rat and mouse. NIDA Res Monogr 95:578

    CAS  Google Scholar 

  23. Aceto MD, Bowmen ER, May EL, Woods JH, Smith CB, Medzihradsky F, Jacobson AE (1989) Very long-acting narcotic antagonists: the 14β-p-substituted cinnamoylaminomorphinones and their partial mu agonist codeinone relatives. Arzneim-Forsch Drug Res 39:570–575

    CAS  Google Scholar 

  24. McLaughlin JP, Hill KP, Jiang Q, Sebastian A, Archer S, Bidlack JM (1999) Nitrocinnamoyl and chlorocinnamoyl derivatives of dihydrocodeinone: in vivo and in vitro characterization of μ-selective agonist and antagonist activity. J Pharmacol Exp Ther 289:304–311

    CAS  Google Scholar 

  25. Comer SD, Burke TF, Lewis JW, Woods JH (1992) Clocinnamox: a novel, systemically active irreversible opioid antagonist. J Pharmacol Exp Ther 262:1051–1056

    CAS  Google Scholar 

  26. Burke TF, Woods JH, Lewis JW, Medzihradsky F (1994) Irreversible opioid antagonist effects of clocinnamox on opioid analgesia and mu receptor binding in mice. J Pharmacol Exp Ther 271:715–721

    CAS  Google Scholar 

  27. Zernig G, Issaevitch T, Broadbear JH, Burke TF, Lewis JW, Brine GA, Woods JH (1995) Receptor reserve and affinity of mu-opioid agonists in mouse antinociception – correlation with receptor-binding. Life Sci 57:2113–2125

    Article  CAS  Google Scholar 

  28. Zernig G, Butelman ER, Lewis JW, Walker EA, Woods JH (1994) In vivo determination of mu opioid receptor turnover in rhesus monkeys after irreversible blockade with clocinnamox. J Pharmacol Exp Ther 269:57–65

    CAS  Google Scholar 

  29. Pitts RC, Allen RM, Walker EA, Dykstra LA (1998) Clocinnamox antagonism of the antinociceptive effects of mu opioids in squirrel monkeys. J Pharmacol Exp Ther 285:1197–1206

    CAS  Google Scholar 

  30. Barrett AC, Smith ES, Picker MJ (2003) Use of irreversible antagonists to determine the relative efficacy of mu-opioids in a pigeon drug discrimination procedure: comparison of beta-funaltrexamine and clocinnamox. J Pharmacol Exp Ther 305:1061–1070

    Article  CAS  Google Scholar 

  31. Walker EA, Young AM (2002) Clocinnamox distinguishes opioid agonists according to relative efficacy in normal and morphine-treated rats trained to discriminate morphine. J Pharmacol Exp Ther 302:101–110

    Article  CAS  Google Scholar 

  32. Broadbear JH, Sumpter TL, Burke TF, Husbands SM, Lewis JW, Woods JH, Traynor JR (2000) Methcinnamox is a potent, long-lasting and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, β-FNA and β-chlornaltrexamine. J Pharmacol Exp Ther 294:933–940

    CAS  Google Scholar 

  33. Zhu J, Lou L-Y, Li J-G, Chen C, Liu-Chen L-Y (1997) Activation of the cloned human kappa opioid receptor by agonists enhances [35S]GTPγS binding to membranes: determination of potencies and efficacies of ligands. J Pharmacol Exp Ther 282:676–684

    CAS  Google Scholar 

  34. Toll L, Berzetei-Gurske IP, Plogar WE, Brandt SR, Adapa ID, Rodriguez L, Schwartz W, Haggart D, O’Brien A, White A, Kennedy JM, Craymer K, Farrington L, Auh JS (1998) Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. NIDA Res Monogr 178:440–445

    CAS  Google Scholar 

  35. Woods JH, Lewis JW, Winger G, Butelman E, Broadbear J, Zernig G (1995) Methoclocinnamox: a μ partial agonist with pharmacotherapeutic potential for heroin abuse. NIDA Res Monogr 147:195–219

    CAS  Google Scholar 

  36. Winger G, Palmer RK, Woods JH (1992) Drug-reinforced responding: rapid determination of dose-response functions. Drug Alcohol Depend 24:135–42

    Article  Google Scholar 

  37. Husbands SM, Lewis JW (2003) Opioid ligands having delayed long-term antagonist activity: potential pharmacotherapies for opioid abuse. Min Rev Med Chem 3:137–144

    Article  CAS  Google Scholar 

  38. Derrick I, Neilan CL, Andes J, Husbands SM, Woods JH, Traynor JR, Lewis JW (2000) 3-Deoxyclocinnamox: the first selective, high affinity, non-peptidic, μ-opioid antagonist lacking a phenolic hydroxyl group. J Med Chem 43:3348–3350

    Article  CAS  Google Scholar 

  39. Lewis JW, Husbands SM, Broadbear J, Woods JH (1995) Opioids – from analgesics to treatment drugs. Franklin M Robinson Memorial Symposium. NIDA Res Monogr 152:67

    Google Scholar 

  40. Moynihan H, Jales AR, Greedy BM, Broadbear JH, Purington L, Traynor JR, Woods JH, Lewis JW, Husbands SM (2009) 14β-O-Cinnamoylnaltrexone and related dihydrocodeinones are mu opioid receptor partial agonists with predominant antagonist activity. J Med Chem 52:1553–1557

    Article  CAS  Google Scholar 

  41. Greiner E, Spetea M, Krassnig R, Schullner F, Aceto M, Harris LS, Traynor JR, Woods JH, Coop A, Schmidhammer H (2003) Synthesis and biological evaluation of 14-alkoxymorphinans. 18. N-Substituted 14-phenylpropyloxymorphinan-6-ones with unanticipated agonist properties: extending the scope of common structure-activity relationships. J Med Chem 46:1758–1763

    Article  CAS  Google Scholar 

  42. Jiang Q, Sebastian A, Archer S, Bidlack JM (1994) 5β-Methyl-14β-(p-nitrocinnamoylamino)-7,8-dihydromorphinone and its corresponding N-cyclopropylmethyl analogue, N-cyclopropylmethylnor-5β-methyl-14β-(p-nitrocinnamoylamino)-7,8-dihydromorphinone: mu selective irreversible opioid antagonists. J Pharmacol Exp Ther 268:1107–1113

    CAS  Google Scholar 

  43. McLaughlin JP, Sebastian A, Archer S, Bidlack JM (1997) 14 Beta-chlorocinnamoylamino derivatives of metopon: long-term mu-opioid receptor antagonists. Eur J Pharmacol 320:121–129

    Article  CAS  Google Scholar 

  44. Bidlack JM, Seyed-Mozaffari A, Archer S (1991) 14β-Thioglycolamido-7, 8-dihydromorphinone, a μ-selective irreversible ligand. Med Chem Res 1:43–46

    CAS  Google Scholar 

  45. Jiang Q, Seyedmozaffari A, Archer S, Bidlack JM (1992) Antinociceptive properties of 2 alkylating derivatives of morphinone – 14-beta-(thioglycolamido)-7,8-dihydromorphinone (TAMO) and 14-beta-(bromoacetamido)-7,8-dihydromorphinone (H2BAMO). J Pharmacol Exp Ther 262:526–531

    CAS  Google Scholar 

  46. Jiang Q, Seyedmozaffari A, Archer S, Bidlack JM (1993) Pharmacological study of 14-beta-(thioglycolamido)-7,8-dihydro-n-cyclopropylmethyl-normorphinone (N-CPM-TAMO). J Pharmacol Exp Ther 264:1021–1027

    CAS  Google Scholar 

  47. Bidlack JM, Frey DK, Kaplan RA, Seyed-Mozaffari A, Archer S (1989) Affinity labelling of mu opioid receptors by sulhydryl alkylating derivatives of morphine and morphinone. Mol Pharmacol 37:50–59

    Google Scholar 

  48. Archer S, Seyedmozaffari A, Jiang Q, Bidlack JM (1994) 14-Alpha, 14′beta-[dithiobis[(2-oxo-2, 1-ethanediyl)imino]]bis (7,8-dihydromorphinone) and 14-alpha, 14′beta-[dithiobis[(2-oxo-2, 1-ethanediyl)imino]]bis[7,8-dihydro-n-(cyclopropylmethyl)normorphinone] – chemistry and opioid binding-properties. J Med Chem 37:1578–1585

    Article  CAS  Google Scholar 

  49. Gatch MB, Negus SS, Mello NK, Archer S, Bidlack JM (1996) Effects of the structurally novel opioid 14 alpha, 14′beta-[dithiobis[(2-oxo-2,1-ethanediyl)imino]]bis(7,8-dihydromorphinone) schedule-controlled behavior and thermal nociception in rhesus monkeys. J Pharmacol Exp Ther 278:1282–1289

    CAS  Google Scholar 

  50. Jiang Q, Seyedmozaffari A, Sebastian A, Archer S, Bidlack JM (1995) Preventing morphine antinociceptive tolerance by irreversible mu-opioid antagonists before the onset of their antagonism. J Pharmacol Exp Ther 273:680–688

    CAS  Google Scholar 

  51. Xu JY, SeyedMozaffari A, Archer S, Bidlack JM (1996) N-Cyclobutylmethyl analog of normorphinone, N-CBM-TAMO: a short-term opioid agonist and long-term mu-selective irreversible opioid antagonist. J Pharmacol Exp Ther 279:539–547

    CAS  Google Scholar 

  52. Archer S, Glick SD, Maisonneuve IM, Bidlack JM, Xu JY, Teitler M, Sebastian A, ElHamouly W, Hutchinson I (1996) Suppression of morphine and cocaine self-administration in rats by a mixed mu antagonist kappa agonist (N-CBM-TAMO) and a long-acting selective D-1 antagonist (AS-300). Bioorg Med Chem Lett 6:1139–1144

    Article  CAS  Google Scholar 

  53. Lewis JW, Neiland NPR, Traynor JR, Woods JH (2000) Pyridylacryloyl derivatives of 14-β-aminomorphinones. NIDA Res Monogr 180:72

    Google Scholar 

  54. Shippenberg TS, Heidbreder C (1995) The delta-opioid receptor antagonist naltrindole prevents sensitization to the conditioned rewarding effects of cocaine. Eur J Pharmacol 280:55–61

    Article  CAS  Google Scholar 

  55. Mori T, Nomura M, Nagase H, Narita M, Suzuki T (2002) Effects of a newly synthesized kappa-opioid receptor agonist, TRK-820, on the discriminative stimulus and rewarding effects of cocaine in rats. Psychopharmacol 161:17–22

    Article  CAS  Google Scholar 

  56. Clayson J, Jales A, Tyacke RJ, Hudson AL, Nutt DJ, Lewis JW, Husbands SM (2001) Selective δ-opioid receptor ligands: potential PET ligands based on naltrindole. Bioorg Med Chem Lett 11:939–943

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy and Pharmacology, University of Bath, Bath, BA2 7AY, UK

    John W. Lewis & Stephen M. Husbands

Authors
  1. John W. Lewis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen M. Husbands
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephen M. Husbands .

Editor information

Editors and Affiliations

  1. School of Pharmaceutical Sciences, Dept. Medicinal Chemistry, Kitasato University, Sirokane 5-9-1, Tokyo, 108-8641, Japan

    Hiroshi Nagase

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Lewis, J.W., Husbands, S.M. (2010). 14-Amino-4,5-Epoxymorphinan Derivatives and Their Pharmacological Actions. In: Nagase, H. (eds) Chemistry of Opioids. Topics in Current Chemistry, vol 299. Springer, Berlin, Heidelberg. https://doi.org/10.1007/128_2010_89

Download citation

Publish with us

Policies and ethics

Search

Navigation